Understand the source comparison
comparison
AICAR vs MOTS-C: Two Paths to AMPK AICAR and MOTS-C flip the same AMPK switch by two different routes. Both show promise in mice, neither is proven in humans. The mechanism split. MOTS-C vs Metformin for Longevity: Key Differences One is a 70-year-old diabetes
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- AICAR vs MOTS-C: Two Paths to AMPK
- AICAR and MOTS-C flip the same AMPK switch by two different routes. Both show promise in mice, neither is proven in humans. The mechanism split.
- MOTS-C vs Metformin for Longevity: Key Differences
- One is a 70-year-old diabetes drug, the other a mitochondrial peptide found in 2015. How MOTS-c and metformin compare on evidence, safety, and cost.
- SLU-PP-332 vs MOTS-c: Two Exercise Mimetics
- Synthetic ERR pan-agonist vs mitochondria-encoded AMPK activator. Same goal, opposite philosophies, and the stack rationale that ties them.
- SS-31 vs MOTS-c: Mitochondrial Peptides
- SS-31 stabilizes cardiolipin, MOTS-c activates AMPK — different targets, different results. Full comparison with dosing and research.